"We're going to have a stronger second half than first half, and we're confident in that." That was the message from Haleon's chief executive, Brian McNamara, to analysts on 30 July, as the consumer health group behind Sensodyne, Advil and Centrum set out its half-year numbers.
Haleon (LSE:HLN), a FTSE 100 constituent, reported sequential improvement in the second quarter, a wider adjusted operating margin, double-digit growth in adjusted Earnings Per Share and a higher interim dividend. It also reiterated its full-year guidance. The market was not fully convinced, however, and the shares slipped on the day as some investors questioned whether sales growth was strong enough to meet the company's targets.
A better second quarter in a tough market
Haleon's results for the six months to 30 June showed Revenue of £5,602m, up 2.2%, with organic revenue growth of 2.6%. Growth picked up in the second quarter after a slow start to the year, and McNamara described a "good first half performance in what remains a challenging consumer environment, with sequential improvement in Q2".
North America, the group's largest market, was a key part of that improvement. Organic growth there reached 3.1% in the second quarter, ahead of market expectations, which Haleon attributed to growth initiatives and execution. Emerging markets also performed strongly, with the company highlighting China and India, while Europe remained tougher.
Oral health was again the standout category. Organic growth of 6.2% in the second quarter was led by Sensodyne and parodontax, supported by innovation. Haleon said 73% of its Business gained or maintained market share, a measure it uses to show its brands are holding their ground against rivals.
Margins and cash do the heavy lifting
Profitability improved faster than sales. The adjusted Operating Margin rose to 24.3%, an increase of 120 basis points at constant currency, and adjusted earnings per share rose 12.0% to 10.3p. On a reported basis, operating profit fell 2.6% to £1,172m, a reminder that headline and adjusted figures can tell different stories.
Cash generation was solid. Free Cash Flow rose by £35m to £769m, giving the group room to keep reducing Debt while returning cash to shareholders. Haleon had completed £457m of its £500m share buyback programme and declared an Interim Dividend of 2.4p, an increase of 9%, in line with its policy of paying a third of the prior year's dividend.
Full-year guidance was reiterated rather than raised. Haleon still expects organic revenue growth of 3% to 5% and high single-digit growth in adjusted operating profit at constant currency. Its medium-term ambition remains annual organic revenue growth of 4% to 6%, with high single-digit growth in adjusted operating profit.
Why investors are watching the growth rate so closely
Haleon was spun out of GSK in 2022 and has since presented itself as a steady compounder, pairing modest sales growth with margin expansion and strong cash flow. That model depends on continued organic growth, because cost savings alone cannot keep lifting earnings indefinitely.
Its portfolio spans oral health, vitamins, minerals and supplements, pain relief, respiratory health and digestive health, sold in pharmacies, supermarkets and online around the world. Many of these are everyday products that consumers buy regardless of the economic cycle, which is why the shares are often grouped with defensive consumer staples in the FTSE 100. That reputation also means investors expect reliability, and even small shortfalls in growth can weigh on sentiment.
The first-half figure of 2.6% sits below the bottom of the full-year range, which means the company needs a stronger second half to meet its guidance. McNamara pointed to growth in emerging markets and an expected recovery in cough-and-cold Demand as reasons for confidence.
The wider consumer health sector has faced a mixed backdrop. Household budgets remain under pressure in several markets, retailers are pushing own-label alternatives, and weather-driven categories such as cold and flu remedies can swing from year to year. Against that, Haleon's brands have strong recognition and pricing power, which helped it expand margins even as volumes grew only modestly.
Where the doubters see risk
Not everyone was persuaded. Some analysts argued that stronger underlying sales growth was needed to justify confidence in the outlook.
Respiratory health was a weak spot. Sales in the category fell 6.5% in the second quarter, a steeper decline than the 3.4% drop in the first quarter, and European growth was close to flat. If the expected recovery in cough and cold does not come through this winter, hitting the full-year range will become harder.
Costs present another challenge. McNamara acknowledged higher freight costs linked to conflicts in some regions, although he said the company could absorb them through gross margin improvement without raising prices. Currency movements, tariffs and competition from cheaper alternatives could also weigh on growth and margins.
The next tests for Haleon
The next scheduled update is Haleon's third-quarter trading statement, which the company has typically released in late October. It will be the first chance to judge whether the second-half acceleration McNamara promised is under way, especially in North America and respiratory health.
The cold and flu season will be important, given its influence on the respiratory category. Innovation in oral health, where Sensodyne and parodontax have been driving growth, will remain a focus, as will signs of whether North America can build on its second-quarter improvement. Investors will also watch progress on the remaining share buyback, and any update on how freight costs and tariffs are affecting margins. Full-year results early next year will show whether Haleon has delivered on its guidance for organic growth and adjusted operating profit.
Conclusion
For Haleon (LSE:HLN), the half-year results showed a business growing its margins, earnings and dividend while sales growth improved from a weak first quarter. Management is confident of a stronger second half, but first-half growth sits below the guided range and respiratory sales are falling. The coming months will decide whether that confidence is borne out or whether the doubters prove right.






Please wait processing your request...